Display options
Cite
Zhang T, Liu Z, Wang J, et al. Seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus among HIV-negative people in China. Infect Agent Cancer. 2017;12:32doi: 10.1186/s13027-017-0142-9.
Zhang, T., Liu, Z., Wang, J., Minhas, V., Wood, C., Clifford, G. M., He, N., & Franceschi, S. (2017). Seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus among HIV-negative people in China. Infectious agents and cancer, 1232. https://doi.org/10.1186/s13027-017-0142-9
Zhang, Tiejun, et al. "Seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus among HIV-negative people in China." Infectious agents and cancer vol. 12 (2017): 32. doi: https://doi.org/10.1186/s13027-017-0142-9
Zhang T, Liu Z, Wang J, Minhas V, Wood C, Clifford GM, He N, Franceschi S. Seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus among HIV-negative people in China. Infect Agent Cancer. 2017 May 30;12:32. doi: 10.1186/s13027-017-0142-9. eCollection 2017. PMID: 28572838; PMCID: PMC5450136.
Copy Download .nbib Format: NLM
Share it on

Infect Agent Cancer. 2017 May 30;12:32. doi: 10.1186/s13027-017-0142-9. eCollection 2017.

Seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus among HIV-negative people in China.

Infectious agents and cancer

Tiejun Zhang, Zhenqiu Liu, Jun Wang, Veenu Minhas, Charles Wood, Gary M Clifford, Na He, Silvia Franceschi

Affiliations

  1. Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
  2. Key Laboratory of Public Health Safety (Fudan University), Ministry of Education, Shanghai, China.
  3. Nebraska Center of Virology and the School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, USA.
  4. International Agency for Research on Cancer, 69372 Lyon, Cedex 08 France.

PMID: 28572838 PMCID: PMC5450136 DOI: 10.1186/s13027-017-0142-9

Abstract

BACKGROUND: Little information on the prevalence of Kaposi's sarcoma associated herpesvirus (KSHV) among HIV-negative individuals is available from Asia.

METHODS: In the present study, we report findings from a new survey of KSHV in 983 HIV-negative male migrants from Shanghai and their combination with previous similar surveys of 600 female migrants, 600 female sex-workers (FSW), 1336 sexually transmitted infection (STI) clinic male patients, 439 intravenous drug-users (IVDU), and 226 men having sex with men (MSM) from China. KSHV-specific antibodies against latent and lytic antigens were assessed using Sf9 and BC3 monoclonal immunofluorescence assay. Age-adjusted prevalence ratios (PR) and 95% confidence interval (95% CI) for KSHV-positivity were estimated using Poisson regression.

RESULTS: In total, 4184 HIV-negative participants were included. KSHV prevalence ranged from 9.8% (95% CI: 7.9%-11.7%) in male migrants to 32.3% (95% CI: 24.1%-34.1%) in MSM. IVDU show intermediate level (17.5%, 95%CI: 14.1%-21.4%). KSHV was associated with syphilis (PR = 2.03, 95% CI: 1.38-2.98) in MSM but not in other groups. An association with human herpes virus 2 was also found among MSM (PR = 1. 83, 95%: 1.22-2.75) but not in migrant workers or FSW.

CONCLUSIONS: KSHV prevalence in HIV-negative heterosexuals, FSW, and STI male patients from China is approximately 10%, but 2- and 3-fold higher in IVDU and MSM, respectively. Associations of KSHV with STIs among MSM only suggest that sexual transmission of the virus is important in MSM but not in heterosexuals.

Keywords: China; Kaposi’s sarcoma associated herpesvirus; Prevalence

References

  1. J Infect Dis. 1999 Sep;180(3):600-6 - PubMed
  2. Semin Oncol. 2015 Apr;42(2):191-206 - PubMed
  3. J Med Virol. 2016 Feb;88(2):304-11 - PubMed
  4. Epidemiol Infect. 2013 Sep;141(9):1823-30 - PubMed
  5. Clin Vaccine Immunol. 2008 Aug;15(8):1259-64 - PubMed
  6. J Med Virol. 2004 Apr;72(4):656-60 - PubMed
  7. Int J Cancer. 2016 Jan 1;138(1):45-54 - PubMed
  8. N Engl J Med. 2001 Mar 1;344(9):637-43 - PubMed
  9. Int J Cancer. 2005 Jun 10;115(2):296-300 - PubMed
  10. Emerg Infect Dis. 2012 Jan;18(1):150-2 - PubMed
  11. N Engl J Med. 2006 Sep 28;355(13):1331-8 - PubMed
  12. Viruses. 2014 Jun 23;6(6):2519-30 - PubMed
  13. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32 - PubMed
  14. Ann Epidemiol. 2008 Jul;18(7):517-21 - PubMed
  15. J Infect Dis. 2002 Jun 15;185(12):1808-12 - PubMed
  16. N Engl J Med. 1998 Apr 2;338(14):948-54 - PubMed
  17. J Med Virol. 2000 Mar;60(3):290-3 - PubMed
  18. Br J Cancer. 2008 Sep 2;99(5):800-4 - PubMed
  19. Am J Epidemiol. 2000 Feb 1;151(3):213-24 - PubMed
  20. Nat Med. 1996 Aug;2(8):918-24 - PubMed
  21. J Infect Dis. 2003 Mar 15;187(6):974-81 - PubMed
  22. BMC Infect Dis. 2014 Feb 05;14 :58 - PubMed
  23. Int J Cancer. 2007 Mar 1;120(5):1129-35 - PubMed

Publication Types

Grant support